Amarin Corp plc (ADR)
NASDAQ: AMRN
$6.68
-$0.08 (-1.2%)
Closing price June 5, 2020
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
2 days ago
Last Updated: 2 days ago
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
4 days ago
While Amarin supports research into Vascepa's possible use in treating COVID-19, the financial benefits promise to be greater if Vascepa's patents are upheld. Of course, Wall Street is bound to lift...
8 days ago
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
10 days ago
Last Updated: 10 days ago
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
15 days ago
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
18 days ago
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock instead of the...
24 days ago
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
29 days ago
Last Updated: 29 days ago
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
1 month ago
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin viable going...
1 month ago
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
2 months ago
Tuesday's top analyst upgrades and downgrades included Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP Semiconductors, Salesforce.com, Sirius XM, Slack and Yelp.
2 months ago
Last Updated: 2 months ago
Amarin has been right in the middle of this recent market sell-off, and while shares have been halved, the stock could be poised for a strong recovery. All the pieces seem to be there.
2 months ago
Friday's top analyst calls included Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle and Slack.
2 months ago
Last Updated: 2 months ago
Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.
3 months ago